Chemotherapy Response and Toxicities in Older Adults with Hodgkin Lymphoma
Authors: Meza Jessica , Huaman Jose , Roque Katia , Enriquez Daniel J , Castro-Mollo Melanie Wendy , Andrade de Mello Ramon , Haro-Varas Juan Carlos , Lopez Chavez Lourdes ISABEL , Quintana Shirley , Alcarraz Cindy , Mallma Soto Victor IVAN , Vasquez Jule F 
Published: December 2023

INTRODUCTION
Hodgkin lymphoma (HL) is a lymphoid malignancy characterized by high-rate responses to conventional chemotherapy (CT). However, older adults are usually undertreated and develop poor outcomes, mainly due to their limited functional status, comorbidities and toxicities concerns. We evaluated the characteristics and outcomes of patients with HL older than 65 years in a real-life limited setting.
METHODS
We performed a retrospective study based on medical records review of newly diagnosed HL between 2004 and 2019 at Instituto Nacional de Enfermedades Neoplasicas (INEN, Lima- Peru). The initial treatment options were classified into three categories: (1) Curative CT regimen, (2) palliative treatment, or (3) no treatment. The staging was done according to Ann Arbor Staging Classification and response were defined by RECIST criteria in patients who received at least 3 courses of CT.
RESULTS
73 patients were included. Median age was 73 years (range 65- 88y). Among the patients, 61% were male, and the remaining 39% were female. Majority of the patients (61%) presented B symptoms. The details of the presentation features are shown in Table 1. The most common histology was classic HL mixed cellularity (46%); although it could not be determined in 19% of patients. At diagnosis, 86% (n=63) of patients had an ECOG performance status of 0-2. Bulky disease was present in 20% of patients (n=15), and 15% (n=11) had visceral involvement. 26% were classified as early-stage (stage I-II), while 74% had advanced disease (stage III-IV).
Regarding treatment, 67.1% (n=49) of the patients received curative CT with ABVD or AVD regimen. A smaller proportion, 4.1% (n= 3), received palliative treatment, and 28.7% (n=28) did not receive any treatment. In patients who received curative CT, 13 patients only received 1 or 2 courses of CT and were subsequently excluded from the analysis. 47% (17/36 patients) achieved complete response, 41.6% partial response (15/36 patients) and 11.1% had progression disease (4/36 patients). In this group of patients, the most common adverse effects observed were hematologic toxicity (22.2%). Additionally, one patient presented pneumonia, and three patients developed pneumonitis. Two patients who presented pneumonitis experienced treatment-related mortality (Table 2).
CONCLUSIONS
In conclusion, this study provided insights into the characteristics and treatment outcomes of older adults with classic Hodgkin lymphoma. The results suggest that curative chemotherapy with ABVD or AVD regimen is the most common treatment approach, with a significant proportion of patients achieving complete response. However, treatment-related adverse effects, particularly pneumonitis, were noted, warranting careful monitoring and management during the treatment process. Further research and careful assessment of treatment protocols are necessary to improve the outcomes and quality of life for this patient population.